A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition

• Status: Unknown status
• Trial end date: 2021-03-28
• Target enrollment: 0
• Participant gender: All

Summary

The investigation is a randomized, double-blind, placebo involved and multi-center clinical trial. All subjects are assigned to 2 groups, including Oryz-Aspergillus Enzyme and Pancreatin tablet group (treatment group) and the placebo group (control group). Treatment group includes 99 subjects, while control group includes 33 subjects. They receive investigational drug 2 tablets/times, tid, p.o. for 180 days.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd.
• Treatments: Pancreatin; Pancrelipase

Criteria

Inclusion Criteria:

• The age is range from 18 to 70 years old.

• Sex is not limited.

• Confirmed cirrhosis (pathologic or radiological rationale) with a mid-upper arm muscle circumference (MAMC) < 90% of the standard value.

• The subject or his family (guardians) agreed to participate in the study and signed the informed consent form.

Note: MAMC formula: mid-arm muscle circumference (cm) = mid-arm circumference (cm) - 3.14 × triceps skinfoldthickness. Standard values: 25.3 cm for adult males and 23.2 cm for adult females.

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

• Pregnant, lactating women or women who do not exclude the possibility of pregnancy;

• Total serum bilirubin ≥ 5 times the upper limit of normal;

• Serum creatinine ≥ 1.2 times the upper limit of normal;

• Prothrombin time ≥ 18 seconds;

• Those who have an allergy to Oryz-Aspergillus Enzyme and Pancreatin Tablet and their related ingredients;

• Subjects who are not able to eat orally for any reason;

• Subjects with a history of previous intestinal obstruction;

• Subjects with acute abdominal pain within 2 months prior to the start of the study;

• Subjects with electrolyte (sodium, potassium, chlorine) disorders that cannot be corrected prior to the start of the study, if electrolyte (sodium, potassium, chlorine) disorders have occurred, have been corrected and stabilized for more than 1 month prior to the start of the study;

• Subjects with prior hepatic encephalitic stage II or higher;

• History of refractory ascites with moderate or higher ascites within 2 weeks prior to the start of the study;

• Subjects with symptoms of gastrointestinal bleeding such as melena and hematemesis within 2 weeks prior to the start of the study;

• Those who have used antibiotics within 2 weeks prior to the start of the study;

• Subjects who experienced other conditions that could affect the study: Subjects who had acquired or primary, secondary immune system conditions (except primary autoimmune liver disease) such as major cardiopulmonary disease, diabetes mellitus, tumors, HIV infection, and other conditions that required long-term hormonal therapy;

• Substance abuse: Alcohol abuse (80 g/day) for < 6 months with a history of intravenous or/and inhaled drugs (drugs) in the last two years;

• Subjects with chronic viral hepatitis B/C who started and/or adjusted their antiviral regimen within 6 months prior to the start of the study;

• Subjects with a history of surgery within 6 months prior to the start of the study;

• Subjects with autoimmune liver disease who started or adjusted their regimen within 6 months prior to the start of the study (i.e., subjects who have started treatment for the aetiology with no change in treatment regimen and drug dose in the new addition of ursodeoxycholic acid or hormones, immunosuppressants, etc., in June)

• Those who participated in other drug trials within 3 months prior to the start of the study;

• Any subject who is considered by the investigator to be unable to participate in the study.